.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Julphar
Express Scripts
Deloitte
Argus Health
Baxter
Federal Trade Commission
Johnson and Johnson
Medtronic
US Army

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201739

« Back to Dashboard

NDA 201739 describes AUVI-Q, which is a drug marketed by Kaleo Inc and is included in one NDA. It is available from one supplier. There are twenty-three patents protecting this drug. Additional details are available on the AUVI-Q profile page.

The generic ingredient in AUVI-Q is epinephrine. There are nineteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

Summary for 201739

Tradename:1
Applicant:1
Ingredient:1
Patents:23
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 201739

Suppliers and Packaging for NDA: 201739

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AUVI-Q epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 201739 NDA kaleo, Inc 60842-021 60842-021-01 2 DOSE PACK in 1 CARTON (60842-021-01) > .1 mL in 1 DOSE PACK
AUVI-Q epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 201739 NDA kaleo, Inc 60842-022 60842-022-01 2 DOSE PACK in 1 CARTON (60842-022-01) > .15 mL in 1 DOSE PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUSStrengthEQ 0.3MG/DELIVERY
Approval Date:Aug 10, 2012TE:BXRLD:Yes
Patent:► SubscribePatent Expiration:Jun 1, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jan 15, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Oct 30, 2028Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Deloitte
Argus Health
Boehringer Ingelheim
Farmers Insurance
Moodys
Cipla
Mallinckrodt
Chubb
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot